In the 1970s, there was widespread doubt in Britain over the safety of the
DTP vaccine for diphtheria, tetanus and pertussis (whooping cough).
The
DTP vaccine would provide shield to the children against diphtheria, pertussis and tetanus.
The
DTP vaccine is a shield against diphtheria, pertussis and tetanus.
Since the introduction of
DTP vaccine in 1981, the overall incidence of pertussis dropped dramatically by late eighties.
In these three regions in 2016, 11 million infants did not receive their first dose of
DTP vaccine, and 18 million did not receive their first dose of MCV.
Until the 1990s, the
DTP vaccine, which includes a whole pertussis bacterium, was highly effective at preventing pertussis but could cause febrile seizures, an adverse event that proved too intolerable for many families.
(4) Prior to this, the suggestion in the 1970s that the
DTP vaccine was related to infant brain damage resulted in vaccination rates for the
DTP vaccine dropping to 30% in Britain, (5) a situation that led to three major outbreaks of whooping cough over a 12-year period, 300,000 notifications and over 70 deaths.
(118) Indeed, in 1985 alone, plaintiffs filed a total of 100 lawsuits against just one manufacturer, Lederle Laboratories, claiming injury following the administration of its
DTP vaccine, which eclipsed the number of lawsuits filed against Lederle in the previous three years combined.
While measles, BCG, and smallpox vaccines have beneficial nonspecific effects,
DTP vaccine appears to have a negative effect, particularly in females.
Immunization visits are scheduled for 6 10 and 14 wks of age when
DTP vaccine and OPV are administered.